Abstract IgG4-related disease is a newly defined disease characterized by elevated serum IgG4 levels and infiltration of affected organs by IgG4-positive plasma cells. Recently, increased IgG4 levels were reported to be closely related with malignancy. To assess the relationship between IgG4 and the progression of gastric cancer, we immunohistochemically stained in this study gastric cancer tissue samples for IgG4-positive cells using an anti-IgG4 antibody. In addition, preand postoperative serum concentrations of IgG4 were measured, using an enzyme-linked immunosorbent assay. In gastric cancer samples, the number of CD138-positive plasma cells was significantly lower and the number of IgG4-positive cells significantly higher than in non-cancerous gastric mucosa. The number of IgG4-positive cells was significantly correlated with gross tumor appearance, tumor depth, lymph node metastasis, venous invasion, and lymphatic invasion. Prognosis was significantly poorer in patients with a high number of IgG4-positive cells than in those with a low number. Multivariate analysis indicated that both the number of IgG4-positive cells and the depth of tumor invasion were independently prognostic of survival. In conclusion, in gastric cancer, the number of IgG4-positive cells is increased and this is closely associated with gastric cancer progression.
Introduction
Cancer immunotherapy is now receiving considerable attention in the treatment of various tumor types because of the success of immune-checkpoint inhibitors, such as antibodies to programmed cell death protein 1 and cytotoxic T lymphocyte antigen-4 [1] [2] [3] . These successes have indicated that an effective immune response to cancer cells can be induced even in cancer patients. Many cancer cells express tumor antigens, rendering them susceptible to recognition and lysis by T cells [4] . However, spontaneous rejection of established cancers is rare, because cancers frequently use physiological immunosuppressive mechanisms to escape from host immunity, a phenomenon known as "tumor immune evasion."
Cancers have been reported to evade host immune systems via several mechanisms, including decreased expression of human leukocyte antigen [5] , secretion of immunosuppressive cytokines including interleukin (IL)-10 and transforming growth factor-beta by cancer cells and cancer stromal cells [6] , and upregulation of immune checkpoint molecules such as programmed cell death-1 and T cell immunoglobulin and mucin domain-3 [7, 8] . Regulatory T cells (Treg), described as CD4+CD25+Foxp3+ cells, which constitute around 10 % of peripheral CD4+ T cells, are crucial for maintaining immune self-tolerance and homeostasis and are involved in mechanisms of immune suppression [9, 10] . Treg cells utilize a wide range of suppressive mechanisms, including the secretion of immunosuppressive cytokines such as IL-10 and transforming growth factor-beta, and the expression of cytotoxic T lymphocyte antigen-4 [11] [12] [13] . Treg cell populations are increased in blood and tumor tissue of cancer patients and are closely correlated with the progression of various types of cancer via immunosuppression [14] [15] [16] .
Recently, B cells as well as T cells were shown to be involved in tumor immune evasion. B cells respond to stimuli by differentiating, undergoing class switching, and producing antibodies of specific classes and subclasses [17] . Human B cells produce four subclasses of immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4; these subclasses differ in biological function and the ability to activate immune system components [18, 19] . IgG4 is a minor immunoglobulin subtype, accounting for 3-6 % of the total IgG circulating in normal subjects [20] . IgG4 shows relatively poor ability to bind complement components and Fc receptors and to activate effector cells. IgG4 has been associated with allergen-specific IgE responses in the pathophysiology of allergic disorders [21] .
IgG4 has recently attracted worldwide attention because of the identification of IgG4-related disease (IgG4-RD). IgG4-RD is characterized by elevated serum IgG4 levels, infiltration of affected organs by IgG4-positive plasma cells, and a variable degree of fibrosis with a characteristic "storiform" pattern [22] [23] [24] . However, the relationship between IgG4 and malignancy remains largely unexplored, although IgG4+ cells were reported to infiltrate extrahepatic cholangiocarcinomas and pancreatic cancers [25] . Abnormal serum titers of IgG4 have been observed in patients with melanoma [26] , and IgG4 was recently reported to significantly impair the potency of tumoricidal IgG1 in a human melanoma xenograft mouse model [17] . Serum IgG4 was shown to correlate inversely with survival in patients with melanoma [17] . Furthermore, IgG4 has been recently reported to be a predictor of risk for disease progression in melanoma [27] . Taken together, these findings suggest that IgG4 may be related to a previously unexplored aspect of tumor-induced immune escape.
Gastric cancer is one of the most common cancers in Asia and has the second highest mortality rate among all cancers worldwide [28] . Despite the expression of tumor rejection antigens such as melanoma antigens 1-3 [29] and the presence of tumor-specific cytotoxic T cells [30] , the immune system fails to mount an effective immune response against gastric carcinoma cells, similar to findings in other cancers. However, the mechanisms by which gastric cancer cells overcome an antitumor immune response are poorly understood. Helicobacter pylori infection has been reported to be associated with both the pathogenesis of gastric cancer and that of the IgG4-RD autoimmune pancreatitis [31] [32] [33] . Moreover, assessment of 108 Japanese patients with IgG4-RD pancreatitis identified 18 cancers in 15 patients, gastric cancer being the most common tumor type [34] . With regard to associations between IgG4-RD and malignancy, Asano et al. reported a close association between IgG4-RD and development of malignancy within 12 years after diagnosis, particularly during the first year, with gastric cancer as the second common tumor type [35] . These findings indicate that IgG4 antibodies may be closely associated with gastric cancer. In this study, therefore, we evaluated the presence of IgG4-positive plasma cells in tumor tissue and the relationship between their presence and gastric cancer progression.
Materials and methods

Patients and normal donors
We enrolled in this study 195 patients with a histopathological diagnosis of gastric adenocarcinoma and treated at Tottori University Hospital. None of these patients received radiotherapy, chemotherapy, or other medical interventions before surgery. Of 131 patients (96 males and 35 females), tissue samples were immunohistochemically stained, and of 137 (96 males and 41 females, mean age 65.1 ± 11.4 years), serum samples were subjected to enzyme-linked immunosorbent assay (ELISA). Healthy controls for ELISA included 26 agematched subjects (17 males and 9 females, of mean age 67.2 ± 10.3 years). All subjects provided informed consent for blood and tissue donations. Clinicopathological findings were generally determined according to the 14th edition of the Japanese Classification of Gastric Carcinoma [36] .
Immunohistochemistry
Tissue samples were fixed in formalin and embedded in paraffin. Serial sections were cut at 4 μm, deparaffinized in xylene and rehydrated through a graded alcohol series. For retrieval of IgG4, the tissue sections were incubated with Histofine protease-based solution (Nichirei) for 7 min, while for retrieval of CD138, the sections were boiled for 15 min in a microwave oven in citrate buffer (pH 9.0). The samples were incubated in 3 % hydrogen peroxidase for 10 min to block endogenous peroxidases, and in Block Ace (DS Pharma Biomedical) for 20 min to prevent non-specific antigen binding. The slides were subsequently incubated with primary antibodies, mouse monoclonal anti-IgG4 (Nichirei, Japan), and mouse monoclonal anti-CD138 (Nichirei), for 1 h at room temperature. Primary antibody binding was detected with Histofine MAX-PO (Nichirei), and immunoreactivity was developed with Histofine DAB Solution (Nichirei). Sections were finally counterstained with Mayer's hematoxylin.
Each slide was dehydrated through a graded alcohol series and coverslipped. The presence of cells positive for IgG4 and CD138 on each slide was determined without knowledge of clinicopathological data. Cells in parts of each tumor where IgG4-and CD138-positive cells were present in high numbers were counted in a ×400 high-power field.
Immunofluorescence staining
Immunofluorescence double staining for IgG4 together with CD138 was performed on 2-μm-thick sections of snap-frozen tissue. After cutting, the sections were air-dried for 30 min and fixed in 4 % formaldehyde for 15 min. They were rinsed three times for 5 min in phosphate-buffered saline (PBS). Incubation with mouse monoclonal anti-IgG4 (Nichirei) for 1 h at room temperature was followed by incubation with rabbit polyclonal anti-CD138 (Bioss antibodies, MA, USA, working dilution 1:100) overnight at 4°C. Subsequently, the slides were incubated for 90 min in the dark with Goat antiMouse IgG conjugated with Alexa Fluor 488 and Goat antiRabbit IgG conjugated with Alexa Fluor 594 (Thermo fisher scientific, MA, USA, working dilution 1:200). The slides were then rinsed (3 × 5 min) in PBS. All slides were mounted with ProLong Gold antifade reagent with 4,6-diamidino-2-phenylindole (Thermo Fisher Scientific) and examined using fluorescence microscopy (BX53, Olympus, Tokyo, Japan).
Measurement of serum IgG4
Serum samples were collected from the patients prior to and 1 month after operation. Concentrations of IgG4 were measured by ELISA using a Human IgG4 Platinum ELISA kit (eBioscience, CA, USA).
Statistical analysis
Between group differences were analyzed by paired t tests or Mann-Whitney U tests. Disease-specific survival (DSS) was calculated according to the Kaplan-Meier method and compared using the log-rank test. Patients who died of causes other than gastric cancer were considered lost to follow-up at the time of death. The Youden index was calculated using receiver operating characteristic (ROC) analysis to determine an optimal cutoff value for the number of IgG4-positive cells for survival analysis. Multivariate analysis of factors prognostic of DSS was performed using Cox proportional hazards model in a stepwise procedure. Statistical significance was defined as p < 0.05. Statistical analyses were performed with GraphPad Prism (GraphPad Software, La Jolla, CA, USA) and StatView 5.0 for Windows (SAS Institute, Cary, NC, USA) software.
Results
Plasma cells and IgG4-positive cells in non-cancerous gastric mucosa and gastric cancer
We first determined the number of plasma cells, defined as CD138-positive cells, and IgG4-positive cells in the tissue of non-cancerous gastric mucosa and gastric cancer. In gastric cancer tissue, the number of plasma cells was significantly lower (Fig. 1) , while the number of IgG4-positive cells was significantly higher (Fig. 2 ) than in non-cancerous gastric mucosa. By immunohistochemistry of serial sections and double staining by immunofluorescence IgG4-positive cells in gastric cancers were also CD138-positive, indicating that most IgG4-positive cells were plasma cells (Fig. 3a-c) . Table 1) .
Prognostic significance of the number of IgG4-positive cells in gastric cancer tissue
We next investigated the prognostic significance of the number of IgG4-positive cells in tumor tissue. Of the 131 patients assessed for this variable, 128 underwent R0 resection, and these were included in further analysis. ROC analysis found that 10 cells per high-power field (HPF) had the highest Youden index (sensitivity + specificity − 1) and was an optimal cutoff value for the number of IgG4-positive cells in gastric cancer (AUC 0.718, 95 % CI 0.608-0.829) (Fig. 4) . Using this cutoff, we classified the patients into two groups, 71 (55.5 %) with <10 (low) and 57 (44.5 %) with ≥10 (high) IgG4-positive cells per HPF. The 5-year DSS rates of these two groups differed significantly (90.3 vs. 43.4 %, p = 0.0003) (Fig. 5a) . Using a Cox proportional hazards model and a stepwise procedure, we found that a high number of IgG4-positive cells were independently prognostic of poorer survival, as was greater depth of tumor invasion (Table 2 ). Since the depth of invasion was also an independent prognostic indicator by multivariate analysis, we analyzed prognosis of gastric cancer patients based on the number of IgG4-positive cell and the depth of invasion. The 5-year survival rate of patients who had advanced gastric cancer with high IgG4 cells was 35.3 %, that of advanced gastric cancer with low IgG4 cells or early gastric cancer with high IgG4 cells 79 %, and that of early gastric cancer with low IgG4 cells 100 %. These differences are statistically significant (p < 0.0001). 
Serum concentrations of IgG4 in gastric cancer patients and healthy controls
We also compared pre-and postoperative serum IgG4 concentrations in gastric cancer patients with IgG4 concentrations in healthy controls. Preoperative serum IgG4 concentrations were significantly lower in advanced gastric cancer patients (n = 71) than in healthy controls (n = 26) (65.7 ± 62.2 vs. 90.2 ± 63.9 mg/dL, p = 0.0453) (Fig. 6 ). In contrast, preoperative serum IgG4 concentrations were similar in patients with early gastric cancer (n = 66) and healthy controls (n = 26) (90.1 ± 86.8 vs. 90.2 ± 63.9 mg/dL, p = 0.57). In patients with gastric cancer, the mean serum IgG4 concentration was significantly higher 1 month after surgery than preoperatively (112.5 ± 93.0 vs. 88.5 ± 82.7 mg/ dL, p < 0.0001) (Fig. 7) . [37, 38] . Marked infiltration of IgG4- positive cells was recently reported in cholangiocarcinoma, in close association with IL-10 predominant regulatory cytokine milieu generated by the tumors cells, both directly and indirectly [25] . We previously showed that gastric cancer cells express IL-10 and that serum IL-10 concentrations tend to be higher in gastric cancer patients than in normal controls [39, 40] . Furthermore, the number of Treg cells, the main source of IL-10, was found to be increased in blood and tumor tissue of gastric cancer patients [41] . We therefore postulate that the increase we observed in IgG4-positive cells in gastric cancer tissue is associated with IL-10 expression.
Alternatively, cancer cells or gastric stromal cells may attract IgG4-positive plasma cells. Interactions between the chemokine CCL1 and the chemokine receptor CCR8 may be involved in the recruitment of IgG4-positive cells in patients with IgG4-related type 1 autoimmune pancreatitis and primary sclerosing cholangitis [42] . In this regard, we have preliminary immunohistochemical data indicating that gastric cancer cells express CCL1 (data not shown). We found that the preoperative serum concentration of IgG4 is significantly lower in patients with advanced gastric cancer than in healthy controls. Moreover, serum IgG4 concentrations were significantly higher in gastric cancer patients after than before surgery, postoperative concentrations being almost equivalent to those of normal controls. These results support the hypothesis that gastric cancer and/or gastric stromal cells attract IgG4-positive cells from the peripheral blood to the site of the cancer. Further investigations are needed to clarify the mechanisms underlying the abundance of IgG4-positive cells in gastric cancer tissue.
The function of IgG4 in tumor tissue is poorly understood. Because IL-10 plays a primary role both in suppressing immune responses and generating IgG4-positive plasma cells, the IgG4 reactions observed in the current study may reflect evasion of immune surveillance. An engineered tumor antigen-specific IgG4 was found to be ineffective in triggering effector cell-mediated tumor killing in vitro [17] . Furthermore, IgG4 significantly impaired the potency of tumoricidal IgG1 in a human melanoma xenograft mouse model [17] . We found that an increased number of IgG4-positive cells in gastric cancer tissue are significantly associated with poor prognosis. Moreover, multivariate analysis showed that both the number of IgG4-positive cells in tumor tissue and the depth of tumor invasion are independently prognostic of DSS. Therefore, the accumulation of IgG4-positive cells in gastric cancer may inhibit immune reactions against tumor cells, resulting in tumor progression. It is therefore of interest that the number of IgG4-positive cells was significantly higher in Borrmann 3 and 4 than in other gastric cancers. These cancers, especially Borrmann 4 gastric cancers, are characterized by rapid cancer cell infiltration and proliferation, accompanied by extensive stromal fibrosis. Increased proliferation of stromal fibroblasts within scirrhous gastric carcinoma lesions and peritoneal metastatic sites suggests that stromal fibroblasts support the progression of this disease [43] . IgG4-RD is also characterized by a variable degree of fibrosis [22] [23] [24] . Therefore, IgG4-positive cells in gastric cancer tissue may be involved in increased fibrosis, resulting in poorer prognosis. In line with this notion, we found that the number of IgG4-positive cells tended to be higher in scirrhous-and intermediate-type tumors than in medullary-type tumors.
The close relationship between the number of IgG4-positive cells and poor patient prognosis suggests that IgG4-positive cells may be a target for the treatment of gastric cancer. Moreover, serum concentrations of IgG4 may be useful in predicting tumor recurrence and patient prognosis. Additional studies are needed to substantiate these ideas.
Our study is the first to show that the number of IgG4-positive plasma cells is increased in gastric cancer tissue, in association with poor prognosis. An increase in the number of IgG4-positive cells may be an important mechanism involved in the progression of gastric cancer. Understanding the details of this mechanism may lead to novel treatment approaches.
